TMCnet News
Insys Addresses Arizona Attorney General ComplaintPHOENIX, Sept. 01, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) (“INSYS” or “the Company”) today released the following statement: We continue to reiterate our efforts to be part of the solution to the opioid crisis by focusing on assisting patients and developing alternative pain medications in our research and development programs. The solutions to this serious national challenge require serious commitment by, and coordination between, governmental authorities, manufacturers, prescribers, patients and other stakeholders in the healthcare community. Encompassed in our desire to bring solutions is our continuing commitment to take responsibility for actions by our former employees and ensure high standards of integrity from our current employees. Recent statements made in connection with the Arizona Attorney General’s investigation of our Company lack context and factual accuracy, particularly as they relate to the causes of the opioid crisis in the State of Arizona. We set forth below some of the relevant facts for consideration:
About INSYS Insys Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve the quality of life of patients. Using proprietary sublingual spray technology and capabilities to develop pharmaceutical cannabinoids, INSYS is developing a pipeline of products intending to address unmet medical needs and the clinical shortcomings of existing commercial products. INSYS currently markets SUBSYS® (fentanyl sublingual spray) and SYNDROS™ (dronabinol oral solution), a proprietary, orally administered liquid formulation of dronabinol. INSYS is committed to developing medications for potentially treating addiction to opioids, opioid overdose, epilepsy, and other disease areas with a significant unmet need. SUBSYS® and SYNDROS™ are trademarks of Insys Development Company, Inc., a subsidiary of Insys Therapeutics, Inc. NOTE: All trademarks and registered trademarks are the property of their respective owners. Forward-Looking Statements This press release contains forward-looking statements including regarding our (i) belief that it is not factually accurate to state that Insys has materially contributed to the opioid crisis in the State of Arizona and (ii) hope that Insys can focus on solution-based initiatives regarding the opioid crisis. These forward-looking statements are based on management's expectations and assumptions as of the date of this press release; actual results may differ materially from those in these forward-looking statements as a result of various factors, many of which are beyond our control. These factors include, but are not limited to risk factors described in our filings with the United States Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2016 and subsequent updates that may occur in our Quarterly Reports on Form 10-Q. Forward-looking statements speak only as of the date of this press release and we undertake no obligation to publicly update or revise these statements, except as may be required by law. Investor Contact: Lisa M. Wilson President 212-452-2793 |